Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
iRhythm shares have further upside despite 70% rally, says Citi » 06:30
06/18/20
06/18
06:30
06/18/20
06:30
IRTC

iRhythm

$116.31 /

-0.32 (-0.27%)

iRhythm Technologies…

iRhythm Technologies shares have increased 70% year-to-date as investor concerns regarding reimbursement changes have waned and the potential benefit from telemedicine has been clarified, Citi analyst Joanne Wuensch tells investors in a research note. Yet with almost 14% of the shares remaining short, and the Citi quant team assigning a "low 22% crowding score" out of 100%," there is more room for upside, says the analyst. While adoption of iRhythm's Zio XT patch for the diagnosis of symptomatic atrial arrhythmias has driven strong double digit growth, increasing 46% in 2019, it is still only 16% penetrated into the traditional monitoring market, notes Wuensch. The analyst reiterates a Buy rating on iRhythm with a $147 price target.

ShowHide Related Items >><<
IRTC iRhythm
$116.31 /

-0.32 (-0.27%)

IRTC iRhythm
$116.31 /

-0.32 (-0.27%)

06/08/20 JPMorgan
iRhythm may benefit from COVID-19 longer term, says JPMorgan
05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
IRTC iRhythm
$116.31 /

-0.32 (-0.27%)

IRTC iRhythm
$116.31 /

-0.32 (-0.27%)

Conference/Events
iRhythm participates in a conference call with SunTrust » 04:55
06/17/20
06/17
04:55
06/17/20
04:55
IRTC

iRhythm

$116.63 /

-0.79 (-0.67%)

Conference call with…

Conference call with management on June 17 hosted by SunTrust.

ShowHide Related Items >><<
IRTC iRhythm
$116.63 /

-0.79 (-0.67%)

IRTC iRhythm
$116.63 /

-0.79 (-0.67%)

06/08/20 JPMorgan
iRhythm may benefit from COVID-19 longer term, says JPMorgan
05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
IRTC iRhythm
$116.63 /

-0.79 (-0.67%)

IRTC iRhythm
$116.63 /

-0.79 (-0.67%)

Conference/Events
iRhythm participates in a conference call with SunTrust » 12:46
06/15/20
06/15
12:46
06/15/20
12:46
IRTC

iRhythm

$113.18 /

+1.97 (+1.77%)

Conference call with…

Conference call with management on June 17 hosted by SunTrust.

ShowHide Related Items >><<
IRTC iRhythm
$113.18 /

+1.97 (+1.77%)

IRTC iRhythm
$113.18 /

+1.97 (+1.77%)

06/08/20 JPMorgan
iRhythm may benefit from COVID-19 longer term, says JPMorgan
05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
IRTC iRhythm
$113.18 /

+1.97 (+1.77%)

IRTC iRhythm
$113.18 /

+1.97 (+1.77%)

Recommendations
iRhythm may benefit from COVID-19 longer term, says JPMorgan » 09:02
06/08/20
06/08
09:02
06/08/20
09:02
IRTC

iRhythm

$119.67 /

-3.9 (-3.16%)

iRhythm is one of the few…

iRhythm is one of the few names in Medical Techology that is well positioned to weather the near-term and potentially benefit from the effects of COVID-19 in the long-term, JPMorgan analyst Robbie Marcus tells investors in a research note. While not immune from headwinds in the near-term, today's environment "has shined a light on iRhythm's unique telehealth platform," which could accelerate the transition to and adoption of Zio, says the analyst. Marcus says a recent survey of 30 physicians points to a ramp in the usage of iRhythm's Home Enrollment system and "significantly fewer headwinds" to hospitals and practices that had previously had telehealth capabilities in place pre-COVID-19. He reiterates an Overweight rating on iRhythm shares with a $140 price target.

ShowHide Related Items >><<
IRTC iRhythm
$119.67 /

-3.9 (-3.16%)

IRTC iRhythm
$119.67 /

-3.9 (-3.16%)

05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
IRTC iRhythm
$119.67 /

-3.9 (-3.16%)

IRTC iRhythm
$119.67 /

-3.9 (-3.16%)

Hot Stocks
iRhythm names Douglas Devine CFO » 16:20
06/04/20
06/04
16:20
06/04/20
16:20
IRTC

iRhythm

$123.58 /

-3.92 (-3.07%)

iRhythm Technologies…

iRhythm Technologies announced that Douglas Devine has been appointed Chief Financial Officer, effective June 22, 2020. Devine will succeed Matthew Garrett, who has decided to step down from the role. Garrett has agreed to assist in a well-ordered transition of his CFO responsibilities and will remain at iRhythm in an advisory role for up to a year to assist with special projects. "On behalf of everyone at iRhythm and our Board of Directors, I want to thank Matt for his many contributions during his tenure with the company, including his strong leadership through iRhythm's IPO and follow-on offering, as well as numerous other transactions that enabled our growth and positioned us well for future financial stability," said Kevin King, CEO. "We appreciate his dedication and wish him all the best beyond iRhythm."

ShowHide Related Items >><<
IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

Hot Stocks
iRhythm CFO Matthew Garrett to step down, Douglas Devine to succeed » 16:18
06/04/20
06/04
16:18
06/04/20
16:18
IRTC

iRhythm

$123.58 /

-3.92 (-3.07%)

iRhythm announced that…

iRhythm announced that Douglas Devine has been appointed CFO, effective June 22. Devine will succeed Matthew Garrett, who has decided to step down from the role. Garrett has agreed to assist in a transition of his CFO responsibilities and will remain at iRhythm in an advisory role for up to a year to assist with special projects. Douglas Devine brings more than 25 years of financial experience to iRhythm, including knowledge in fund raising, influencing business strategy, driving cost reductions and implementing financial systems. He joins the company from GlobalFoundries, where he has been the CFO.

ShowHide Related Items >><<
IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

05/08/20 Canaccord
iRhythm price target raised to $130 from $107 at Canaccord
05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

IRTC iRhythm
$123.58 /

-3.92 (-3.07%)

Over a month ago
Recommendations
iRhythm price target raised to $130 from $107 at Canaccord » 08:50
05/08/20
05/08
08:50
05/08/20
08:50
IRTC

iRhythm

$119.93 /

+10.33 (+9.43%)

Canaccord analyst Jason…

Canaccord analyst Jason Mills raised the firm's price target on iRhythm to $130 from $107 and keeps a Buy rating on the shares. The analyst continues to like its positioning as early trends showcased ramping rep productivity alongside a fairly balanced split in new/same store sales. He also noted the company's quick transition to scale its home enrollment service along with its utility and increasing utilization in the hospital setting.

ShowHide Related Items >><<
IRTC iRhythm
$119.93 /

+10.33 (+9.43%)

05/08/20 SunTrust
iRhythm price target raised to $130 from $102 at SunTrust
03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
01/09/20 William Blair
iRhythm initiated with an Outperform at William Blair
Recommendations
iRhythm price target raised to $130 from $102 at SunTrust » 08:19
05/08/20
05/08
08:19
05/08/20
08:19
IRTC

iRhythm

$119.93 /

+10.33 (+9.43%)

SunTrust analyst Kaila…

SunTrust analyst Kaila Krum raised the firm's price target on iRhythm to $130 from $102 and keeps a Buy rating on the shares. Home enrollment can be challenging to scale, but iRhythm has done it well, the analyst tells investors in a research note. Krum added that while the cardiac monitoring market is evolving, she believes that iRhythm can strengthen its position over the long-term through the initiatives put in place today.

ShowHide Related Items >><<
IRTC iRhythm
$119.93 /

+10.33 (+9.43%)

03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
01/09/20 William Blair
iRhythm initiated with an Outperform at William Blair
01/07/20 SunTrust
iRhythm initiated with a Buy at SunTrust
Earnings
iRhythm remains unable to give accurate FY20 guidance » 16:30
05/07/20
05/07
16:30
05/07/20
16:30
IRTC

iRhythm

$120.04 /

+10.44 (+9.53%)

iRhythm withdrew its…

iRhythm withdrew its previously announced FY20 guidance on April 9. Given the uncertain scope and duration of the COVID-19 pandemic, the company remains unable to accurately estimate the impact of the pandemic on its future operations and financial results.

ShowHide Related Items >><<
IRTC iRhythm
$120.04 /

+10.44 (+9.53%)

03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
01/09/20 William Blair
iRhythm initiated with an Outperform at William Blair
01/07/20 SunTrust
iRhythm initiated with a Buy at SunTrust
Earnings
iRhythm reports Q1 EPS (34c), consensus (59c) » 16:30
05/07/20
05/07
16:30
05/07/20
16:30
IRTC

iRhythm

$120.04 /

+10.44 (+9.53%)

Reports Q1 revenue…

Reports Q1 revenue $63.5M, consensus $61.41M.

ShowHide Related Items >><<
IRTC iRhythm
$120.04 /

+10.44 (+9.53%)

03/04/20 Citi
iRhythm initiated with a Buy at Citi
01/10/20
Fly Intel: Top five analyst initiations
01/09/20 William Blair
iRhythm initiated with an Outperform at William Blair
01/07/20 SunTrust
iRhythm initiated with a Buy at SunTrust

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.